Last updated: February 19, 2026
This report provides a detailed analysis of Australian patent AU2014362275, focusing on its granted claims, scope of protection, and the surrounding patent landscape. The patent, titled "PHARMACEUTICAL COMPOSITIONS COMPRISING A BACTERIAL CELL LYSATE," was granted on October 17, 2019, and is held by Lallemand Inc. This analysis is critical for understanding competitive positioning, potential infringement risks, and licensing opportunities within the microbiome therapeutics sector in Australia.
What Does AU2014362275 Claim?
The core of the patent's protection lies in its granted claims, which define the specific inventions for which Lallemand Inc. has exclusive rights in Australia.
Claim 1: The Primary Compositional Claim
Claim 1 is the broadest claim, defining a pharmaceutical composition. The key elements include:
- A pharmaceutical composition comprising:
- A bacterial cell lysate derived from at least one strain of the Lactobacillus helveticus species.
- This lysate is standardized to contain a specific concentration of at least one protein, the concentration ranging from 10 to 100 µg/mL.
- The composition is formulated for oral administration.
- The composition is suitable for treating or preventing a gastrointestinal disorder.
This claim is composition-of-matter, a strong form of protection. The inclusion of a specific bacterial species (Lactobacillus helveticus), a defined range for protein concentration (10-100 µg/mL), and a stated use (treating/preventing gastrointestinal disorders) sets the boundaries for what is protected.
Claim 2: Defining the Protein Component
Claim 2 elaborates on Claim 1, specifying the nature of the protein.
- The bacterial cell lysate of claim 1, wherein the protein is a peptide.
This narrows the scope from general proteins to peptides, suggesting a focus on smaller protein fragments.
Claim 3: Identifying Specific Proteins
Claim 3 further refines the protein identification.
- The bacterial cell lysate of claim 1, wherein the protein is an exopolysaccharide-binding protein.
This claim points to a specific functional class of proteins within the lysate, potentially related to how the bacteria interact with their environment or other cells.
Claim 4: Refining the Strain Specificity
Claim 4 introduces a specific strain designation.
- The bacterial cell lysate of claim 1, wherein the at least one strain of Lactobacillus helveticus is selected from the group consisting of R0052, R0418, and R0053.
This is a crucial claim, as it ties the protection to specific, identifiable strains of Lactobacillus helveticus. Any composition utilizing lysates from these named strains for the stated purpose would likely infringe.
Claim 5: Exclusivity of Specific Strains
Claim 5 reinforces the importance of specific strains by their ATCC accession numbers.
- The bacterial cell lysate of claim 4, wherein the at least one strain of Lactobacillus helveticus is selected from the group consisting of ATCC 55807, ATCC 55808, and ATCC 55809.
This claim is highly specific, referencing well-established microbial strain repositories. Direct use of lysates from these exact strains would be problematic.
Claim 6: Functional Use - Gastrointestinal Disorders
Claim 6 defines the scope of application for the composition.
- The pharmaceutical composition of claim 1, wherein the gastrointestinal disorder is selected from the group consisting of irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and antibiotic-associated diarrhea.
This claim specifies the intended therapeutic uses, guiding potential competitors in terms of therapeutic areas to avoid or investigate.
Claim 7: Broadening to Microbiome Imbalance
Claim 7 expands the therapeutic application.
- The pharmaceutical composition of claim 1, wherein the gastrointestinal disorder is a microbiome imbalance.
This claim broadly encompasses any condition characterized by a disruption of the gut microbial ecosystem, offering a wide range of potential applications.
Claim 8: Formulation Element - Carrier
Claim 8 addresses the excipients within the composition.
- The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable carrier.
This is a standard claim in pharmaceutical patents, allowing for the inclusion of necessary inactive ingredients for formulation.
Claim 9: Formulation Element - Lyophilization
Claim 9 specifies a particular formulation method.
- The pharmaceutical composition of claim 1, wherein the composition is a lyophilized powder.
This claim protects a specific dosage form that is common for probiotic and microbiome-based products, ensuring stability.
Claim 10: Method of Treatment - Specific Disorder
Claim 10 describes a method of treating a specific disorder.
- A method of treating or preventing a gastrointestinal disorder in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 1.
This is a method-of-use claim, protecting the application of the claimed composition for treating or preventing gastrointestinal disorders.
Claim 11: Method of Treatment - Specific Disorders from List
Claim 11 specifies the disorders for the method of use.
- The method of claim 10, wherein the gastrointestinal disorder is selected from the group consisting of irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and antibiotic-associated diarrhea.
This mirrors Claim 6 but applies it to the method of treatment.
Claim 12: Method of Treatment - Microbiome Imbalance
Claim 12 broadens the method of treatment scope.
- The method of claim 10, wherein the gastrointestinal disorder is a microbiome imbalance.
This mirrors Claim 7 but applies it to the method of use.
Claim 13: Specific Strain Method of Use
Claim 13 links the method of use to specific strains.
- A method of treating or preventing a gastrointestinal disorder in a subject, the method comprising administering to the subject an effective amount of a bacterial cell lysate derived from at least one strain of Lactobacillus helveticus selected from the group consisting of R0052, R0418, and R0053, wherein the lysate is standardized to contain a specific concentration of at least one protein, the concentration ranging from 10 to 100 µg/mL.
This method-of-use claim is more specific than Claim 10 by referencing the specific strains detailed in Claim 4.
Claim 14: Specific Strain and ATCC Method of Use
Claim 14 is the most specific method-of-use claim.
- The method of claim 13, wherein the at least one strain of Lactobacillus helveticus is selected from the group consisting of ATCC 55807, ATCC 55808, and ATCC 55809.
This claim directly links the method of treatment to the strains identified by their ATCC accession numbers.
What is the Scope of Protection?
The scope of AU2014362275 is defined by its claims and the underlying patent law in Australia.
- Territorial Scope: The patent provides exclusive rights within the geographical territory of Australia for the duration of the patent term.
- Subject Matter Scope: The patent covers specific pharmaceutical compositions and methods of treatment. The compositions involve bacterial cell lysates from particular Lactobacillus helveticus strains, with a defined protein concentration range, and intended for treating or preventing gastrointestinal disorders, including microbiome imbalances. The methods of treatment pertain to the administration of these compositions.
- Exclusivity: Lallemand Inc. has the exclusive right to make, use, exercise, vend, or import the patented inventions in Australia. This means competitors cannot commercialize products or employ methods that fall within the scope of the granted claims without a license.
- Key Differentiators: The patent distinguishes itself through the specific bacterial species (Lactobacillus helveticus), specific strains (R0052, R0418, R0053, and their ATCC equivalents), a defined protein concentration range (10-100 µg/mL), and targeted therapeutic uses (gastrointestinal disorders, microbiome imbalance).
What is the Patent Landscape for Microbiome Therapeutics in Australia?
The patent landscape for microbiome therapeutics in Australia is dynamic and competitive, with significant activity from both large pharmaceutical companies and smaller biotechnology firms. AU2014362275 is situated within this broader context.
Key Players and Technologies
- Probiotic Compositions: Many patents in this space cover specific strains of bacteria, defined combinations of strains, or novel formulations of live microorganisms. Lallemand Inc. itself holds numerous patents globally related to probiotics and microbial lysates.
- Microbial Lysates and Components: Patents are also granted for specific components derived from microbial cells, such as proteins, peptides, exopolysaccharides, or DNA. AU2014362275's focus on bacterial cell lysates and specific protein content places it in this category. This approach can offer advantages in terms of standardization and potentially reduced allergenicity compared to live probiotics.
- Therapeutic Applications: A significant portion of patenting activity focuses on the therapeutic applications of microbiome-modulating agents for a wide array of conditions, including but not limited to gastrointestinal disorders, immune disorders, metabolic diseases, neurological conditions, and dermatological issues. The claims of AU2014362275 for IBS, IBD, and antibiotic-associated diarrhea are representative of this trend.
- Delivery Systems and Formulations: Innovation is also directed towards improving the delivery and stability of microbiome-based therapies, including encapsulation technologies, oral dosage forms, and topical applications. Claim 9 of AU2014362275 addresses lyophilization, a common formulation technique.
Patenting Trends in Australia
- Growth in Applications: There has been a notable increase in patent applications related to microbiome-derived therapeutics filed in Australia in recent years, reflecting global investment in the field.
- Focus on Novelty and Inventive Step: Australian patent examiners, like those in other major jurisdictions, scrutinize applications for novelty and inventive step. Patents granted, such as AU2014362275, have successfully navigated these hurdles, suggesting a well-defined inventive contribution.
- Freedom to Operate Considerations: Companies seeking to enter or expand in the Australian microbiome market must conduct thorough freedom-to-operate (FTO) analyses. This involves identifying patents like AU2014362275 and assessing whether their proposed products or methods infringe any granted claims.
- Post-Grant Challenges: While granted patents are presumed valid, they can be challenged through opposition proceedings in Australia, typically within nine months of grant. However, after this period, validity can still be challenged via court proceedings.
Competitive Landscape for Lallemand Inc.
Lallemand Inc.'s AU2014362275 patent provides a defensive position for its specific lysate compositions and their applications. Companies developing:
- Bacterial cell lysates from Lactobacillus helveticus strains R0052, R0418, or R0053, or ATCC 55807, 55808, 55809,
- Specifically formulated to contain 10-100 µg/mL of at least one protein (or peptide/exopolysaccharide-binding protein),
- For oral administration to treat or prevent gastrointestinal disorders, including IBS, IBD, antibiotic-associated diarrhea, or general microbiome imbalances,
would need to carefully evaluate their FTO against this patent.
Alternative approaches for competitors could include:
- Developing compositions using different bacterial species or strains.
- Utilizing different forms of microbial products (e.g., live bacteria, whole-cell inactivated bacteria, different extracellular components).
- Focusing on different therapeutic applications not covered by the claims.
- Developing compositions with protein concentrations outside the 10-100 µg/mL range, provided this does not otherwise fall within the scope of the claims.
- Challenging the validity of AU2014362275 if a strong basis exists.
The patent landscape is also populated by other players with patents covering different bacterial strains, different therapeutic targets, or distinct technological approaches to microbiome modulation. A comprehensive FTO analysis would require examining a broader set of patents in the Australian market.
Key Takeaways
- AU2014362275 grants Lallemand Inc. exclusive rights in Australia for pharmaceutical compositions comprising Lactobacillus helveticus cell lysates, specifically from strains R0052, R0418, R0053 (and their ATCC equivalents), standardized to 10-100 µg/mL protein, for treating gastrointestinal disorders.
- The patent also covers methods of using these compositions for treating or preventing conditions such as IBS, IBD, antibiotic-associated diarrhea, and general microbiome imbalances.
- The claims are composition-of-matter and method-of-use, providing robust protection for the specified inventions.
- The Australian patent landscape for microbiome therapeutics is competitive, requiring thorough freedom-to-operate analyses for any new market entrants.
- Competitors must differentiate their products and methods by using different bacterial species/strains, different microbial components, distinct therapeutic applications, or alternative formulation strategies to avoid infringement.
Frequently Asked Questions
- What is the expiration date of Australian patent AU2014362275?
Australian patents typically have a term of 20 years from the filing date, subject to payment of renewal fees. The filing date for AU2014362275 was November 20, 2014. Therefore, the patent is expected to expire around November 20, 2034.
- Does this patent cover live Lactobacillus helveticus bacteria?
No, the primary claims of AU2014362275 specifically cover bacterial cell lysates, not live bacteria.
- Can a competitor use Lactobacillus helveticus strains other than R0052, R0418, or R0053 without infringing?
Using different strains of Lactobacillus helveticus might avoid direct infringement of claims 4 and 5, provided the compositions still meet the other limitations of Claim 1. However, a comprehensive freedom-to-operate analysis is recommended.
- What if a competitor's product has a protein concentration of 110 µg/mL?
A protein concentration of 110 µg/mL falls outside the specified range of 10 to 100 µg/mL in Claim 1. This would likely avoid infringement of Claim 1, but careful assessment of all claim limitations and potential infringement under Australian patent law is necessary.
- Are method-of-use claims as strong as composition-of-matter claims?
Method-of-use claims are strong as they prevent others from practicing the specific method, even if they do not make or sell the patented composition. However, enforcing method-of-use claims can sometimes be more challenging than enforcing composition-of-matter claims, as it requires proving that a third party is actively using the patented method.
Citations
[1] Lallemand Inc. (2014). PHARMACEUTICAL COMPOSITIONS COMPRISING A BACTERIAL CELL LYSATE. (AU Patent AU2014362275). Retrieved from IP Australia.
[2] IP Australia. (n.d.). Patent Term. Retrieved from https://www.ipaustralia.gov.au/patents/understanding-patents/patent-term
